Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
Dongna Chen(Cancer Hospital of Huanxing Chaoyang District Beijing), Yutao Liu(Shanghai University), Mingzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Weihua Li(Capital Medical University), Lin Li(Anhui Agricultural University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xingsheng Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Lv(Liaoning Normal University), Meng Fan, Lin Yang(Alberta Health Services)
Cited by 1
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents
|PLoS ONE|2017|614
The Genetic and Environmental Factors for Keratoconus
|BioMed Research International|2015|418
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Consensus recommendations for trabecular meshwork cell isolation, characterization and culture
|Experimental Eye Research|2018|345